Literature DB >> 26149459

Manipulating the in vivo immune response by targeted gene knockdown.

Judy Lieberman1.   

Abstract

Aptamers, nucleic acids selected for high affinity binding to proteins, can be used to activate or antagonize immune mediators or receptors in a location and cell-type specific manner and to enhance antigen presentation. They can also be linked to other molecules (other aptamers, siRNAs or miRNAs, proteins, toxins) to produce multifunctional compounds for targeted immune modulation in vivo. Aptamer-siRNA chimeras (AsiCs) that induce efficient cell-specific knockdown in immune cells in vitro and in vivo can be used as an immunological research tool or potentially as an immunomodulating therapeutic.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26149459      PMCID: PMC4498257          DOI: 10.1016/j.coi.2015.06.005

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  79 in total

1.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

2.  Systematic selection of modified aptamer pairs for diagnostic sandwich assays.

Authors:  Urs A Ochsner; Louis S Green; Larry Gold; Nebojsa Janjic
Journal:  Biotechniques       Date:  2014-03-01       Impact factor: 1.993

3.  Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo.

Authors:  S R Watson; Y F Chang; D O'Connell; L Weigand; S Ringquist; D H Parma
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2000-04

4.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

Review 5.  Therapeutic RNA aptamers in clinical trials.

Authors:  Padma Sundaram; Helena Kurniawan; Mark E Byrne; Jacek Wower
Journal:  Eur J Pharm Sci       Date:  2012-11-07       Impact factor: 4.384

6.  Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.

Authors:  Fernando Pastor; Despina Kolonias; James O McNamara; Eli Gilboa
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

7.  Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs.

Authors:  Yi Shu; Farzin Haque; Dan Shu; Wei Li; Zhenqi Zhu; Malak Kotb; Yuri Lyubchenko; Peixuan Guo
Journal:  RNA       Date:  2013-04-19       Impact factor: 4.942

8.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

Review 9.  Current progress on aptamer-targeted oligonucleotide therapeutics.

Authors:  Justin P Dassie; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2013-12

10.  Selection of a novel DNA aptamer for assay of intracellular interferon-gamma.

Authors:  Beibei Cao; Yan Hu; Jinhong Duan; Jie Ma; Danke Xu; Xian-Da Yang
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

View more
  4 in total

Review 1.  Tapping the RNA world for therapeutics.

Authors:  Judy Lieberman
Journal:  Nat Struct Mol Biol       Date:  2018-04-16       Impact factor: 15.369

2.  Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.

Authors:  Ying Zhang; Xuemei Xie; Pourya Naderi Yeganeh; Dian-Jang Lee; David Valle-Garcia; Karla F Meza-Sosa; Caroline Junqueira; Jiayu Su; Hongbo R Luo; Winston Hide; Judy Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 3.  Current Advances in Aptamers for Cancer Diagnosis and Therapy.

Authors:  Shin-Ichiro Hori; Alberto Herrera; John J Rossi; Jiehua Zhou
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

4.  Lactate dehydrogenase B regulates macrophage metabolism in the tumor microenvironment.

Authors:  Ann-Christin Frank; Rebecca Raue; Dominik C Fuhrmann; Evelyn Sirait-Fischer; Carsten Reuse; Andreas Weigert; Dieter Lütjohann; Karsten Hiller; Shahzad Nawaz Syed; Bernhard Brüne
Journal:  Theranostics       Date:  2021-06-04       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.